Common adverse events include upper respiratory tract infections (e.g., common cold, sinus infections), headache, hypertension, and transient transaminase elevations. While most reactions are mild, clinicians must be vigilant for severe infusion-related events, which require immediate intervention and potentially ABG assessment.
For patients on tocilizumab, standard monitoring focuses on signs of infection (e.g., fever, chills), liver function (ALT/AST), and blood cell counts (neutrophils, platelets). However, clinicians should escalate to ABG analysis if respiratory distress is suspected. tocil abg
The safety profile of TCZ is generally favorable, with common adverse events including: liver function (ALT/AST)